Smruthi Organics Limited manufactures and markets active pharmaceutical ingredient (API) products to India. The company operates through Bulk Drugs and Drugs Intermediates (API), and Formulation segments. The company provides API for cardiovascular, such as amlodipine besilate, losartan potassium, telmisartan, s - amlodipine besilate, s - amlodipine malelate, and valsartan; for anti diabetic, which comprises metformin HCL, vildagliptin, teneligliptin, and dapagliflozin; and for anti infectives that consists of diloxanide furoate, norfloxacin, and pefloxacin mesylate, as well as ticagrelor for anti platelets. It also offers drug intermediates, such as amlodipine base, s-amlodipine base, and phthaloyl amlodipine. In addition, the company is developing empagliflozin for anti-diabetics; and apixaban and rivaroxaban for anti-platelets. It also exports its products. The company was incorporated in 1989 and is headquartered in Solapur, India.
Rs. Crores · hover row for definition
Metric
Jun 2026
Mar 2026
Dec 2025
Sep 2025
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Sales 29.30
29.05
22.29
31.60
18.85
38.09
31.25
29.39
27.27
39.66
23.48
29.59
34.91
Expenses 23.49
25.15
18.29
26.59
18.56
33.41
27.08
26.50
26.82
35.58
24.66
25.16
30.29
Operating Profit 5.81
3.90
4.00
5.01
0.29
4.68
4.17
2.89
0.45
4.08
-1.18
4.43
4.62
OPM % 19.83
13.43
17.95
15.85
1.54
12.29
13.34
9.83
1.65
10.29
-5.03
14.97
13.23
Other Income -0.04
-0.07
-0.44
0.01
0.04
0.08
0.00
0.01
0.00
0.06
0.00
0.00
0.01
Depreciation 1.60
1.75
1.67
1.51
1.41
1.50
1.37
1.33
1.29
1.59
1.45
1.38
1.24
Interest 0.31
0.31
0.25
0.66
0.46
0.52
0.51
0.44
0.41
0.37
0.32
0.39
0.33
Profit before tax 3.86
1.77
1.64
2.85
-1.54
2.74
2.29
1.13
-1.25
2.18
-2.95
2.66
3.06
Tax % 25.65
39.55
14.63
27.72
-28.57
18.61
35.37
31.86
-26.40
30.73
-22.03
22.56
25.49
Net Profit 2.88
1.07
1.40
2.06
-1.10
2.23
1.48
0.78
-0.92
1.52
-2.29
2.07
2.29
EPS in Rs 2.52
0.93
1.22
1.80
-0.96
1.95
1.29
0.68
-0.80
1.33
-2.00
1.81
2.00
Annual · Rs. Crores
Metric
Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Mar 2018 Mar 2017 Mar 2016 Mar 2015
Sales
102.00 126.00 128.00 141.00 133.00 126.00 131.00 137.00 97.00 79.00 74.00 77.00
Expenses
89.00 114.00 116.00 131.00 115.00 98.00 116.00 121.00 94.00 69.00 63.00 72.00
Operating Profit
13.00 12.00 12.00 10.00 18.00 29.00 15.00 17.00 3.00 10.00 11.00 5.00
OPM %
13.00 10.00 9.00 7.00 14.00 23.00 12.00 12.00 3.40 13.00 14.00 6.00
Other Income
0.00 0.00 0.00 0.00 1.00 1.00 4.00 1.00 0.00 1.00 0.00 0.00
Interest
2.00 2.00 1.00 1.00 1.00 1.00 3.00 4.00 4.00 4.00 5.00 6.00
Depreciation
6.00 6.00 6.00 5.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 5.00
Profit before tax
5.00 5.00 5.00 4.00 14.00 24.00 12.00 10.00 -5.00 3.00 2.00 -6.00
Tax %
27.00 27.00 28.00 8.00 25.00 29.00 30.00 30.00 -31.00 39.00 55.00 -33.00
Net Profit
3.00 4.00 4.00 4.00 10.00 17.00 8.00 7.00 -3.00 2.00 1.00 -4.00
EPS in Rs
3.00 3.11 3.14 3.61 9.07 14.95 7.41 6.02 -2.82 1.39 0.63 -3.34
Dividend Payout %
50.00 48.00 48.00 55.00 33.00 20.00 14.00 11.00 0.00 0.00 0.00 0.00
Annual · Rs. Crores — latest first
Metric
Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Mar 2018 Mar 2017 Mar 2016 Mar 2015
Equity Capital
11.00 11.00 11.00 11.00 11.00 11.00 4.00 4.00 4.00 4.00 4.00 4.00
Reserves
62.00 60.00 58.00 57.00 56.00 49.00 39.00 33.00 25.00 28.00 27.00 26.00
Borrowings
8.00 17.00 12.00 6.00 3.00 10.00 16.00 28.00 31.00 33.00 37.00 45.00
Other Liabilities
22.00 23.00 37.00 32.00 18.00 21.00 30.00 37.00 25.00 20.00 35.00 34.00
Total Liabilities
104.00 112.00 118.00 106.00 88.00 92.00 88.00 101.00 85.00 85.00 103.00 109.00
Fixed Assets
47.00 45.00 40.00 37.00 33.00 31.00 32.00 30.00 30.00 30.00 32.00 35.00
CWIP
3.00 3.00 1.00 2.00 1.00 1.00 0.00 2.00 1.00 1.00 1.00 1.00
Investments
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Assets
54.00 64.00 77.00 66.00 53.00 60.00 56.00 69.00 54.00 54.00 69.00 72.00
Total Assets
104.00 112.00 118.00 106.00 88.00 92.00 88.00 101.00 85.00 85.00 103.00 109.00
Annual · Rs. Crores — latest first
Metric
Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Mar 2018 Mar 2017 Mar 2016 Mar 2015
Cash from Operating Activity
22.00 10.00 4.00 12.00 2.00 23.00 21.00 12.00 5.00 9.00 14.00 9.00
Cash from Investing Activity
-9.00 -11.00 -7.00 -10.00 7.00 -3.00 -5.00 -4.00 -3.00 0.00 0.00 -1.00
Cash from Financing Activity
-12.00 1.00 3.00 -2.00 -12.00 -7.00 -17.00 -5.00 -2.00 -9.00 -14.00 -8.00
Net Cash Flow
1.00 0.00 0.00 0.00 -3.00 13.00 -1.00 2.00 0.00 0.00 0.00 -1.00
Free Cash Flow
14.00 -2.00 -4.00 3.00 -4.00 19.00 17.00 7.00 1.00 8.00 13.00 7.00
CFO/OP %
182.00 100.00 46.00 136.00 33.00 101.00 160.00 71.00 159.00 93.00 128.00 184.00
Annual · Days / % — latest first
Metric
Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Mar 2018 Mar 2017 Mar 2016 Mar 2015
Debtor Days
69.00 94.00 117.00 96.00 78.00 62.00 68.00 97.00 95.00 97.00 95.00 103.00
Inventory Days
228.00 151.00 150.00 96.00 91.00 100.00 75.00 92.00 126.00 145.00 166.00 123.00
Days Payable
111.00 85.00 144.00 98.00 50.00 81.00 97.00 120.00 130.00 123.00 128.00 106.00
Cash Conversion Cycle
186.00 160.00 123.00 93.00 118.00 80.00 46.00 68.00 92.00 119.00 133.00 120.00
Working Capital Days
85.00 92.00 94.00 73.00 99.00 52.00 32.00 78.00 7.00 1.00 8.00 2.00
ROCE %
8.00 8.00 8.00 7.00 21.00 39.00 25.00 21.00 -1.00 10.00 9.00 0.00
% holding — latest first
Quarterly
Yearly
Holder
Jun 2026
Mar 2026
Dec 2025
Sep 2025
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023
Promoters
64.73
64.73
64.73
64.73
64.73
64.73
63.87
63.87
63.87
63.84
63.60
63.58
Public
35.27
35.27
35.27
35.28
35.27
35.27
36.13
36.13
36.12
36.16
36.41
36.43
No. of Shareholders
5,959
6,035
6,187
6,356
6,047
5,905
5,959
5,972
5,869
5,877
5,752
5,605
9 records